New drug cocktail targets tough lung cancer
NCT ID NCT03333343
First seen Jan 05, 2026 · Last updated May 24, 2026 · Updated 23 times
Summary
This study tests the safety and early effectiveness of adding another drug (INC280, trametinib, ribociclib, gefitinib, or LXH254) to EGF816 for adults with advanced EGFR-mutant non-small cell lung cancer. About 105 participants will receive one of these combinations. The goal is to find tolerable doses and see if the combinations help control the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR-MUTANT NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novartis Investigative Site
Toronto, Ontario, M5G 2M9, Canada
-
Novartis Investigative Site
Cologne, North Rhine-Westphalia, 50937, Germany
-
Novartis Investigative Site
Essen, 45147, Germany
-
Novartis Investigative Site
Hong Kong, 999077, Hong Kong
-
Novartis Investigative Site
Ancona, AN, 60126, Italy
-
Novartis Investigative Site
Milan, MI, 20162, Italy
-
Novartis Investigative Site
Rozzano, MI, 20089, Italy
-
Novartis Investigative Site
Singapore, 119074, Singapore
-
Novartis Investigative Site
Singapore, 168583, Singapore
-
Novartis Investigative Site
Tainan, 704302, Taiwan
-
Novartis Investigative Site
Taipei, 10002, Taiwan
Conditions
Explore the condition pages connected to this study.